COL6A3 and glioblastoma: Taken together, these data indicate that COL6A3+ TAFs, with their unique extracellular matrix regulatory functions, significantly influence the prognostic outcomes of GBM patients and are a contributing factor to the limited efficacy of neoadjuvant therapy in GBM patients.